Px563L重组炭疽疫苗两剂方案用于暴露后预防的安全性与免疫原性
本研究为1期双盲安慰剂对照剂量递增试验,在54名健康成人中评估Px563L(含mrPA与MPLA佐剂)10、50、80 mcg三个剂量,于第0天和第28天肌内注射。结果显示各剂量耐受良好,无严重不良事件;第二次接种后TNA NF50滴度自第35天至第70天显著升高,几何均值及95%CI下限均超过0.56。结论支持Px563L两剂方案用于炭疽暴露后预防的继续开发。
要点
- Px563L两剂方案(第0天、第28天)在健康成人中耐受良好,无严重不良事件。
- 第二次接种后TNA NF50滴度显著升高,几何均值及95%CI下限超过0.56。
- 10和50 mcg剂量组所有不良事件均为轻度,多为注射部位反应。
核心结论
- Px563L按第0天和第28天两剂肌内注射方案耐受良好,并在第二次接种后7天起诱导保护性抗体反应。
研究设计与样本
- 1期双盲安慰剂对照剂量递增试验,纳入54名健康受试者,评估mrPA 10、50、80 mcg三个剂量。
- 每个剂量组18人按8:8:2随机分配至Px563L(mrPA加佐剂)、RPA563(仅mrPA)或安慰剂(生理盐水)。
- 主要安全性和免疫原性分析在所有受试者完成第70天访视后进行,长期安全性评估至第393天。
主要发现
- 所有剂量Px563L接种均耐受良好,无严重不良事件或导致提前退出的不良事件。
- 所有治疗组中大多数不良事件为注射部位反应,10和50 mcg剂量组所有不良事件均为轻度。
- 主要免疫原性终点TNA NF50滴度在第二次接种Px563L后显著升高,从第35天至第70天几何均值及95%CI下限超过0.56。
关键数值与推荐
- TNA NF50阈值0.56与动物炭疽暴露模型中的显著生存相关。
- Px563L两剂方案间隔28天,肌内注射。
临床怎么用
- Px563L两剂方案(第0天、第28天)在健康成人中显示良好耐受性和保护性抗体反应,支持暴露后预防的继续开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Px563L is a next-generation anthrax vaccine candidate consisting of a protein subunit, mutant recombinant protective antigen SNKE167-ΔFF-315-E308D (mrPA), and liposome-embedded monophosphoryl lipid A (MPLA) adjuvant. Px563L has the potential to deliver an improved safety and immunogenicity profile relative to the currently licensed vaccine, which is produced from filtered B. anthracis culture supernatants. We conducted a Phase 1, double-blind, placebo-controlled, dose-escalation study in 54 healthy subjects to evaluate Px563L at 3 dose levels of mrPA (10, 50, and 80 mcg). For each dose level, 18 subjects were randomized in an 8:8:2 ratio to Px563L (mrPA with adjuvant), RPA563 (mrPA only) or placebo (saline). Each subject received an intramuscular (IM) injection on Day 0 and Day 28. Primary safety and immunogenicity analysis was conducted after all subjects completed the Day70 visit, a duration deemed clinically relevant for post-exposure prophylaxis. Long-term safety was assessed through Day 393. Vaccinations with Px563L at all dose levels were well-tolerated. There were no serious adverse events or adverse events (AE) leading to early withdrawal. In all treatment groups, most AEs were due to injection site reactions, and all AEs at the 10 and 50 mcg dose levels were mild. For the primary immunogenicity endpoint (protective toxin neutralizing antibody 50% neutralization factor [TNA NF50]), titers started to increase significantly after the second administration of Px563L, from Day35 through Day70, with the geometric mean and lower bound of the 95% confidence interval exceeding 0.56, a threshold correlating with significant survival in animal models of anthrax exposure. In conclusion, Px563L, administered as two IM doses 28 days apart, was well-tolerated and elicited a protective antibody response starting at seven days after the second vaccination. These findings support the continued development of Px563L in a two-dose regimen for anthrax post-exposure prophylaxis. ClinicalTrials.gov identifier NCT02655549.
引用
- Schneider JC, Chen HC, Bautista E, et al. Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults. Vaccine. 2021. PMID: 34544599. doi:10.1016/j.vaccine.2021.08.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。